Clinical Trial: Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout

Brief Summary: The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.

Detailed Summary:
Sponsor: CymaBay Therapeutics, Inc.

Current Primary Outcome: Serum uric acid [ Time Frame: Baseline and end of treatment phase (4 wks) ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: CymaBay Therapeutics, Inc.

Dates:
Date Received: April 14, 2011
Date Started: May 2011
Date Completion:
Last Updated: March 30, 2015
Last Verified: March 2015